Inside informationEnglish
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ipsen SA
- Filed
- 13/01/2026, 18:19
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119118_20260113